Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $395K fell 21.9% year over year, ahead of the -86.0% change in trailing-twelve-month cost of revenue. Over 3 fiscal years it compounded at -44.1% a year.

Context

  • Cost of revenue amounted to 26.7% of revenue in FY2025, up 11.8 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -21.9% holds above the trailing-twelve-month pace of -86.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$395K+149.2% QoQ
Last fiscal yearDec 2025
$2.09M-25.1% YoY
LTMMar 2026
$1.98M-86.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.9%——
1 year-25.1%——
3-year CAGR-44.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
2.09M USD
Year-over-year change
-25.1%
4-year CAGR
-18.4%

Cost of Revenue vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -86.0% is the 7th highest of 8, against a peer median of +6.2%.
  • Cost of revenue amounts to 23.7% of revenue for ACRS, versus a peer median of 38.0%.
ACRS Competitors
Cost of Revenue for ACRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TRAXFirst Tracks Biotherapeutics IncFY2025$139.61M USD-8.4%——
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$2.34M USD+7090.5%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M USD-86.0%-44.1%23.7%
ALMSAlumis Inc. Common StockLTM Jun 2026$871K USD+6.2%+140.9%11.8%
ATTOAttovia Therapeutics, Inc.FY2025$804K USD+156.9%—59.6%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$66.6K USD———
IMUXImmunic, Inc.LTM Mar 2026$33K USD-50.0%——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€0 EUR———
ANABAnaptysBio, Inc.LTM Mar 2026-$38.15M USD-122.7%-69.9%16.4%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ACRS) —+6.2%+35.5%38.0%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.